| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 1.87 | 27.3% |
| Total Income | 2.47 | 8.3% |
| Expenditure | 53.98 | 15.8% |
| PBT | -51.52 | 17.2% |
| Net Profit | -51.52 | 17.2% |
| OPM | — | |
| NPM | — | |
| EPS | 2.36 | 16.8% |
Suven Life Sciences Announces Q1 FY 2025-26 Financial Results with INR 8576.40 Million Fund Raising
13 Aug 2025 · 13 Aug 2025, 03:03 pm
Summary
Suven Life Sciences, a Biopharmaceutical company engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders, has announced its unaudited financial results for the quarter ended 30 June 2025. The company has successfully completed its fund raising program to the tune of INR 8576.40 million.
Key Highlights
- 1
R&D and Operational expenses for the quarter ended 30 June 2025 are INR 526.15 million
- 2
Depreciation and Amortisation for the quarter ended 30 June 2025 are INR 13.68 million
- 3
Finance cost for the quarter ended 30 June 2025 is INR 0.23 million
- 4
Clinical development pipeline includes SUVN-502, SUVN-G3031, SUVN-911, SUVN-D4010, and SUVN-I6107
- 5
SUVN-502 is in ongoing phase 3 study for Agitation and Aggression in Alzheimer’s type dementias in North America and Europe
- 6
SUVN-G3031 is preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy
- 7
SUVN-911 has initiated Phase 2B clinical study in USA for Major Depressive Disorder
- 8
SUVN-D4010 is planning for Phase 2 double blind study for the treatment of Cognition
- 9
SUVN-I6107 is ongoing Phase 1 MAD study for establishing safety and pharmacokinetics
Management Comments
Suven Life Sciences Ltd
Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.
Informational and educational content only. Not investment advice.